Poxel – diabetes drug development

Poxel is a biopharma company developing innovative drugs for metabolic diseases, in particular Type 2 diabetes.

Poxel – diabetes drug development


Poxel is a diabetes drug development specialist aiming to find innovative solutions for the management of metabolic diseases. Type 2 diabetes is one of the major health concerns and its incidence is growing rapidly, without any satisfactory therapeutic available. Poxel has a rich pipeline of products with disease-modifying mechanisms of action offering the potential for safer, more effective therapies. Its leading compound, Imeglimin, is in Phase II clinical development for Type 2 diabetes and has already achieved proof-of-concept in two Phase IIa trials. This innovative compound is a tetrahydrotriazine-containing class of oral antidiabetic agents called “glimins” and decreasing mitcohondrial respiration. Imeglimin is able to decrease hepatic glucose production, increase muscle glucose uptake and increase pancreatic glucose-dependent insulin secretion. Poxel is advancing with a second project to develop a direct AMPK activator for the treatment of Type 2 diabetes. AMPK is an enzyme controlling whole-body energy metabolism and playing an important role in the management of diabetes. Compounds being tested in this project have already demonstrated positive effects on glycemia and lipid profiles (triglycerides and cholesterol) in pathophysiological animal models. Furthermore, the GLP-1 (glucagon-like peptide-1) receptor represents a new target for a diabetes drug discovery project at Poxel. GLP-1 is an incretin hormone stimulating insulin secretion in a glucose-dependent manner. It can restore the normal profile of insulin release in response to glucose, a process that is defective in patients with Type 2 diabetes. Poxel is currently developing oral, non-peptide GLP-1 receptor agonists. This project is in the lead optimization phase and has already demonstrated positive effects on insulin secretion in pathophysiological animal models.

Poxel was spun off in 2009 from Merck Serono, a leading global player in the field of metabolic disorders. Poxel is based in Lyon (France). Board of Directors is composed by Thierry Hercend, Raphaël Wisniewski, Olivier Martinez, Bruno Montanari, Thomas Kuhn, Khoso Baluch and Richard Kender. Scientific Advisory Board is composed of prominent scientists in the fields of diabetes, metabolism and drug development (Gerd Bode, Fabrizio Andreelli and Cliff Bailey).

More about Poxel : www.poxel.com

Poxel – metabolic diseases – Type 2 diabetes – Imeglimin – AMPK activator

Poxel – Type 2 diabetes – diabetes drug development – diabetes – drug development – Imeglimin – tetrahydrotriazine – antidiabetic – glimins – mitcohondrial respiration – hepatic glucose production – muscle glucose uptake – insulin secretion – insulin – AMPK – glycemia – triglycerides – cholesterol – GLP-1 – glucagon-like peptide-1 – GLP-1 receptor – Merck Serono – Thierry Hercend – Raphaël Wisniewski – Olivier Martinez – Bruno Montanari – Thomas Kuhn – Khoso Baluch – Richard Kender – Gerd Bode – Fabrizio Andreelli – Cliff Bailey